<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schiff, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Abatacept and Adalimumab Equally Effective for Rheumatoid Arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">To date, few direct comparisons of biologic agents for the treatment of rheumatoid arthritis (RA) have been conducted, resulting in a lack of evidence-based guidance for selection of biologic therapy. The Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Subjects With Background Methotrexate trial [AMPLE; NCT00929864] was the first powered head-to-head study comparing two biologic disease-modifying antirheumatic drugs, abatacept and adalimumab, with the standard of care, methotrexate. This article discusses Phase 3b of the AMPLE trial.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>